cidofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals phosphonic acid derivatives 639 113852-37-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cidofovir
  • cidofovir monophosphate
  • cidovir
  • vistide
  • sidofovir
  • cidofovir dihydrate
  • anhydrous cidofovir
  • cidofovir hydrate
An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.
  • Molecular weight: 279.19
  • Formula: C8H14N3O6P
  • CLOGP: -1.99
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 4
  • TPSA: 145.68
  • ALOGS: -1.38
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 170 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 17.91 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.49 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 26, 1996 FDA GILEAD SCIENCES INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 153.28 62.82 43 1231 22890 63464858
Adenovirus infection 139.49 62.82 28 1246 3543 63484205
BK virus infection 77.60 62.82 17 1257 3262 63484486
Cystitis haemorrhagic 73.73 62.82 17 1257 4106 63483642
Pathogen resistance 66.30 62.82 17 1257 6381 63481367
Nephropathy toxic 64.22 62.82 18 1256 9461 63478287
Cytomegalovirus infection reactivation 63.76 62.82 15 1259 3948 63483800

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 112.99 45.93 41 1303 25886 34929701
Cystitis haemorrhagic 93.96 45.93 25 1319 5654 34949933
Adenovirus infection 91.06 45.93 24 1320 5233 34950354
Off label use 70.81 45.93 83 1261 419441 34536146
Drug ineffective for unapproved indication 58.91 45.93 25 1319 23690 34931897
Cytomegalovirus infection 50.19 45.93 23 1321 26112 34929475
Pathogen resistance 48.79 45.93 17 1327 9465 34946122
Progressive multifocal leukoencephalopathy 48.30 45.93 17 1327 9747 34945840
Renal impairment 46.01 45.93 34 1310 94479 34861108

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 256.24 49.78 82 2504 42131 79699671
Adenovirus infection 200.69 49.78 48 2538 8399 79733403
Cystitis haemorrhagic 151.76 49.78 39 2547 9133 79732669
Pathogen resistance 112.61 49.78 34 2552 14308 79727494
Epstein-Barr virus infection reactivation 101.69 49.78 21 2565 1871 79739931
Off label use 100.76 49.78 134 2452 907081 78834721
Nephropathy toxic 96.85 49.78 33 2553 20386 79721416
Cytomegalovirus infection 96.26 49.78 40 2546 42604 79699198
Immune reconstitution inflammatory syndrome 84.20 49.78 27 2559 13814 79727988
BK virus infection 82.75 49.78 24 2562 8780 79733022
Renal impairment 78.83 49.78 54 2532 157729 79584073
Cytomegalovirus infection reactivation 78.56 49.78 23 2563 8693 79733109
Drug ineffective 71.90 49.78 126 2460 1080787 78661015
Drug ineffective for unapproved indication 64.50 49.78 32 2554 51206 79690596
Cytomegalovirus viraemia 61.86 49.78 21 2565 12800 79729002
Aplastic anaemia 55.01 49.78 21 2565 17884 79723918

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AB12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:47868 photosensitising agent
CHEBI has role CHEBI:64946 anti-AIDS agent
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
CMV Retinitis in AIDS Patients indication
Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients indication
Prevention of Cytomegalovirus Disease off-label use
Acidosis contraindication 51387008
Kidney disease contraindication 90708001 DOID:557
Severe Chronic Neutropenia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.81 acidic
pKa2 12.99 acidic
pKa3 4.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
DNA polymerase catalytic subunit Enzyme INHIBITOR WOMBAT-PK CHEMBL

External reference:

IDSource
4020976 VUID
N0000148447 NUI
D00273 KEGG_DRUG
83170 RXNORM
4020976 VANDF
C0286079 UMLSCUI
CHEBI:59495 CHEBI
L8P PDB_CHEM_ID
CHEMBL152 ChEMBL_ID
DB00369 DRUGBANK_ID
D000077404 MESH_DESCRIPTOR_UI
60613 PUBCHEM_CID
JIL713Q00N UNII
194597 MMSL
4446 MMSL
6016 MMSL
d04028 MMSL
006053 NDDF
108688007 SNOMEDCT_US
386894007 SNOMEDCT_US
149394-66-1 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CIDOFOVIR DIHYDRATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-216 INJECTION, SOLUTION 375 mg INTRAVENOUS ANDA 21 sections
Vistide HUMAN PRESCRIPTION DRUG LABEL 1 61958-0101 INJECTION 75 mg INTRAVENOUS NDA 24 sections
CIDOFOVIR HUMAN PRESCRIPTION DRUG LABEL 1 67457-210 INJECTION, SOLUTION 75 mg INTRAVENOUS ANDA 26 sections